Cargando…

Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy

BACKGROUND: Guidelines recommend left ventricular ejection fraction (LVEF) assessments every 3 months for cardiotoxicity monitoring during human epidermal growth factor receptor 2 (HER2) targeted therapy. Evidence in support of this practice is lacking. OBJECTIVES: This study examines the associatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Anthony F., Moskowitz, Chaya S., Lee Chuy, Katherine, Yang, Ji, Dang, Chau T., Liu, Jennifer E., Oeffinger, Kevin C., Steingart, Richard M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584138/ https://www.ncbi.nlm.nih.gov/pubmed/33103123 http://dx.doi.org/10.1016/j.jaccao.2020.03.002

Ejemplares similares

Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
por: Yu, Anthony F., et al.
Publicado: (2023)

Predicting Adverse Health Outcomes in Long-Term Survivors of a Childhood Cancer
por: Moskowitz, Chaya S., et al.
Publicado: (2014)

Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Examining Cardiotoxicity With HER2 Therapies
por: Denduluri, Neelima
Publicado: (2020)

Benign and Malignant Findings on Chest CT Among Adult Survivors of Childhood and Young Adult Cancer with a History of Chest Radiotherapy
por: Barnea, Dana, et al.
Publicado: (2023)

Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology
por: Steingart, Richard M., et al.
Publicado: (2019)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials
por: Brown, Lauren J., et al.
Publicado: (2021)

Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis
por: Lee Chuy, Katherine, et al.
Publicado: (2020)

T066: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study
por: Dinan, Michaela, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer
por: Guan, Jingyuan, et al.
Publicado: (2021)

Unmasking Hydroxychloroquine Cardiotoxicity in a Patient With Heart Failure and Chronotropic Incompetence
por: Ezzeddine, Fatima M., et al.
Publicado: (2021)

Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology
por: Bergler-Klein, Jutta, et al.
Publicado: (2022)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Twenty years of anti-HER2 therapy-associated cardiotoxicity
por: Pondé, Noam F, et al.
Publicado: (2016)

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
por: Jerusalem, Guy, et al.
Publicado: (2019)

Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
por: Robinson, Emma L., et al.
Publicado: (2023)

Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients
por: Cuomo, Alessandra, et al.
Publicado: (2019)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification
por: Bergom, Carmen, et al.
Publicado: (2021)

Pattern and Prognostic Implications of Cardiac Metastases Among Patients With Advanced Systemic Cancer Assessed With Cardiac Magnetic Resonance Imaging
por: Pun, Shawn C., et al.
Publicado: (2016)

Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model
por: Ahmad, Shafique, et al.
Publicado: (2017)

Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone
por: Vörös, Imre, et al.
Publicado: (2022)

Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy
por: Zhou, Ji-Chao, et al.
Publicado: (2023)

Late-chronic cardiotoxicity and heart failure caused by ibrutinib: a case report and literature review
por: ZHU, Jian, et al.
Publicado: (2021)

Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity
por: Schmidt, Amand F., et al.
Publicado: (2023)

Cardiotoxicity of Molecularly Targeted Agents
por: Hedhli, Nadia, et al.
Publicado: (2011)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
por: Dou, Xiao-qian, et al.
Publicado: (2018)

Diastolic heart failure is a new clinical entity of trastuzumab-induced cardiotoxicity: a case report
por: Fujita, Kana, et al.
Publicado: (2022)

Implementing a mHealth intervention to increase colorectal cancer screening among high-risk cancer survivors treated with radiotherapy in the Childhood Cancer Survivor Study (CCSS)
por: Henderson, Tara O., et al.
Publicado: (2022)

Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer‐Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole‐Body Positron Emission Tomography
por: Chan, Angel T., et al.
Publicado: (2019)

Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies
por: Shamseddine, Achraf, et al.
Publicado: (2022)

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Alhussein, Muhammad Mustafa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jrji0p1274jthnmbn0lsei4m30